268 related articles for article (PubMed ID: 34788506)
21. Mobilization and transduction of peripheral blood progenitor cells in patients with mucopolysaccharidosis I.
Hubel A; Stroncek D; Pan D; Whitley CB; McCullough J
J Hematother; 1998 Dec; 7(6):505-14. PubMed ID: 9919944
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Endovascular and Intraventricular Gene Therapy With Adeno-Associated Virus-α-L-Iduronidase for Hurler Disease.
Janson CG; Romanova LG; Leone P; Nan Z; Belur L; McIvor RS; Low WC
Neurosurgery; 2014 Jan; 74(1):99-111. PubMed ID: 24077583
[TBL] [Abstract][Full Text] [Related]
23. Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access.
Fumagalli F; Calbi V; Natali Sora MG; Sessa M; Baldoli C; Rancoita PMV; Ciotti F; Sarzana M; Fraschini M; Zambon AA; Acquati S; Redaelli D; Attanasio V; Miglietta S; De Mattia F; Barzaghi F; Ferrua F; Migliavacca M; Tucci F; Gallo V; Del Carro U; Canale S; Spiga I; Lorioli L; Recupero S; Fratini ES; Morena F; Silvani P; Calvi MR; Facchini M; Locatelli S; Corti A; Zancan S; Antonioli G; Farinelli G; Gabaldo M; Garcia-Segovia J; Schwab LC; Downey GF; Filippi M; Cicalese MP; Martino S; Di Serio C; Ciceri F; Bernardo ME; Naldini L; Biffi A; Aiuti A
Lancet; 2022 Jan; 399(10322):372-383. PubMed ID: 35065785
[TBL] [Abstract][Full Text] [Related]
24. Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial.
Sessa M; Lorioli L; Fumagalli F; Acquati S; Redaelli D; Baldoli C; Canale S; Lopez ID; Morena F; Calabria A; Fiori R; Silvani P; Rancoita PM; Gabaldo M; Benedicenti F; Antonioli G; Assanelli A; Cicalese MP; Del Carro U; Sora MG; Martino S; Quattrini A; Montini E; Di Serio C; Ciceri F; Roncarolo MG; Aiuti A; Naldini L; Biffi A
Lancet; 2016 Jul; 388(10043):476-87. PubMed ID: 27289174
[TBL] [Abstract][Full Text] [Related]
25. Improved retroviral vector design results in sustained expression after adult gene therapy in mucopolysaccharidosis I mice.
Herati RS; Ma X; Tittiger M; Ohlemiller KK; Kovacs A; Ponder KP
J Gene Med; 2008 Sep; 10(9):972-82. PubMed ID: 18613275
[TBL] [Abstract][Full Text] [Related]
26. Mucopolysaccharidosis type I.
Wraith JE; Jones S
Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():102-6. PubMed ID: 25345091
[TBL] [Abstract][Full Text] [Related]
27. Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome).
Tolar J; Park IH; Xia L; Lees CJ; Peacock B; Webber B; McElmurry RT; Eide CR; Orchard PJ; Kyba M; Osborn MJ; Lund TC; Wagner JE; Daley GQ; Blazar BR
Blood; 2011 Jan; 117(3):839-47. PubMed ID: 21037085
[TBL] [Abstract][Full Text] [Related]
28. Normalization and improvement of CNS deficits in mice with Hurler syndrome after long-term peripheral delivery of BBB-targeted iduronidase.
El-Amouri SS; Dai M; Han JF; Brady RO; Pan D
Mol Ther; 2014 Dec; 22(12):2028-2037. PubMed ID: 25088464
[TBL] [Abstract][Full Text] [Related]
29. Correction of clinical manifestations of canine mucopolysaccharidosis I with neonatal retroviral vector gene therapy.
Traas AM; Wang P; Ma X; Tittiger M; Schaller L; O'donnell P; Sleeper MM; Vite C; Herati R; Aguirre GD; Haskins M; Ponder KP
Mol Ther; 2007 Aug; 15(8):1423-31. PubMed ID: 17519893
[TBL] [Abstract][Full Text] [Related]
30. Outcome of second hematopoietic cell transplantation in Hurler syndrome.
Grewal SS; Krivit W; Defor TE; Shapiro EG; Orchard PJ; Abel SL; Lockman LA; Ziegler RS; Dusenbery KE; Peters C
Bone Marrow Transplant; 2002 Mar; 29(6):491-6. PubMed ID: 11960268
[TBL] [Abstract][Full Text] [Related]
31. Cord-blood transplants from unrelated donors in patients with Hurler's syndrome.
Staba SL; Escolar ML; Poe M; Kim Y; Martin PL; Szabolcs P; Allison-Thacker J; Wood S; Wenger DA; Rubinstein P; Hopwood JJ; Krivit W; Kurtzberg J
N Engl J Med; 2004 May; 350(19):1960-9. PubMed ID: 15128896
[TBL] [Abstract][Full Text] [Related]
32. Analysis of factors affecting development of carpal tunnel syndrome in patients with Hurler syndrome after hematopoietic cell transplantation.
Khanna G; Van Heest AE; Agel J; Bjoraker K; Grewal S; Abel S; Krivit W; Peters C; Orchard PJ
Bone Marrow Transplant; 2007 Mar; 39(6):331-4. PubMed ID: 17277793
[TBL] [Abstract][Full Text] [Related]
33. Autologous Ex Vivo Lentiviral Gene Therapy for Adenosine Deaminase Deficiency.
Kohn DB; Booth C; Shaw KL; Xu-Bayford J; Garabedian E; Trevisan V; Carbonaro-Sarracino DA; Soni K; Terrazas D; Snell K; Ikeda A; Leon-Rico D; Moore TB; Buckland KF; Shah AJ; Gilmour KC; De Oliveira S; Rivat C; Crooks GM; Izotova N; Tse J; Adams S; Shupien S; Ricketts H; Davila A; Uzowuru C; Icreverzi A; Barman P; Campo Fernandez B; Hollis RP; Coronel M; Yu A; Chun KM; Casas CE; Zhang R; Arduini S; Lynn F; Kudari M; Spezzi A; Zahn M; Heimke R; Labik I; Parrott R; Buckley RH; Reeves L; Cornetta K; Sokolic R; Hershfield M; Schmidt M; Candotti F; Malech HL; Thrasher AJ; Gaspar HB
N Engl J Med; 2021 May; 384(21):2002-2013. PubMed ID: 33974366
[TBL] [Abstract][Full Text] [Related]
34. Long-term outcome of Hurler syndrome following bone marrow transplantation.
Whitley CB; Belani KG; Chang PN; Summers CG; Blazar BR; Tsai MY; Latchaw RE; Ramsay NK; Kersey JH
Am J Med Genet; 1993 Apr; 46(2):209-18. PubMed ID: 8484412
[TBL] [Abstract][Full Text] [Related]
35. TALEN-mediated intron editing of HSPCs enables transgene expression restricted to the myeloid lineage.
Seclen E; Jang JC; Lawal AO; Pulicani S; Boyne A; Tkach D; Juillerat A; Duchateau P; Valton J
Mol Ther; 2024 Jun; 32(6):1643-1657. PubMed ID: 38582963
[TBL] [Abstract][Full Text] [Related]
36. Bone marrow transplantation in canine mucopolysaccharidosis I. Effects within the central nervous system.
Shull RM; Hastings NE; Selcer RR; Jones JB; Smith JR; Cullen WC; Constantopoulos G
J Clin Invest; 1987 Feb; 79(2):435-43. PubMed ID: 3100576
[TBL] [Abstract][Full Text] [Related]
37. Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of α-L-iduronidase in mice with mucopolysaccharidosis type I.
Osborn MJ; McElmurry RT; Lees CJ; DeFeo AP; Chen ZY; Kay MA; Naldini L; Freeman G; Tolar J; Blazar BR
Mol Ther; 2011 Mar; 19(3):450-60. PubMed ID: 21081900
[TBL] [Abstract][Full Text] [Related]
38. Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome.
Tolar J; Grewal SS; Bjoraker KJ; Whitley CB; Shapiro EG; Charnas L; Orchard PJ
Bone Marrow Transplant; 2008 Mar; 41(6):531-5. PubMed ID: 18037941
[TBL] [Abstract][Full Text] [Related]
39. Patient iPSC-derived neural stem cells exhibit phenotypes in concordance with the clinical severity of mucopolysaccharidosis I.
Swaroop M; Brooks MJ; Gieser L; Swaroop A; Zheng W
Hum Mol Genet; 2018 Oct; 27(20):3612-3626. PubMed ID: 30052969
[TBL] [Abstract][Full Text] [Related]
40. ZFN-Mediated In Vivo Genome Editing Corrects Murine Hurler Syndrome.
Ou L; DeKelver RC; Rohde M; Tom S; Radeke R; St Martin SJ; Santiago Y; Sproul S; Przybilla MJ; Koniar BL; Podetz-Pedersen KM; Laoharawee K; Cooksley RD; Meyer KE; Holmes MC; McIvor RS; Wechsler T; Whitley CB
Mol Ther; 2019 Jan; 27(1):178-187. PubMed ID: 30528089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]